[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stroke-acute-ischemic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stroke-acute-ischemic":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,40,67,90,115,141,165,189,218,240,272,306,334,355,376,401,427,450],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100516907","trendelenburg-position-for-acute-anterior-circulation-ischemic-stroke-with-large-artery-atherosclerosis-etiology-hopes-3-100516907",false,"NCT06010641","Trendelenburg Position for Acute Anterior Circulation Ischemic Stroke With Large Artery Atherosclerosis Etiology (HOPES 3)","Trendelenburg Position for Acute Anterior Circulation Ischemic Stroke With Large Artery Atherosclerosis Etiology (HOPES 3): a Prospective, Randomized, Open-label, Blinded-endpoint, Multi-center Trial","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Acute ischemic stroke confirmed by NCCT or MRI;\n* Moderate neurologic deficit (6≤ NIHSS ≤ 16) within 24 hours of onset, or progressing from mild (NIHSS ≤ 5) to moderate neurologic deficit (6≤ NIHSS ≤ 16) within 24 hours, requiring ≥ 4 point increase in NIHSS score although the onset time is beyond 24 hours;\n* Probable large artery atherosclerosis etiology based on the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria (responsible artery stenosis ≥ 50% or occlusion);\n* Anterior circulation stroke (internal carotid artery, M1 or M2 of middle cerebral artery);\n* First stroke onset or past stroke without obvious neurological deficit (mRS≤2);\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Pre-stroke disability (mRS≥3);\n* Patients with disturbance of consciousness;\n* Patients who plan to undergo or have completed thrombolysis or mechanical thrombectomy;\n* Hemorrhagic stroke or combined ischemic and hemorrhagic stroke;\n* Serious comorbidity, such as liver or kidney insufficiency, malignant tumor, etc;\n* Other stroke etiologies, such as cardiogenic embolism, arteritis, arterial dissection, moyamoya disease, etc;\n* Previous history of intracerebral hemorrhage within 1 year;\n* Any contraindication to head-down position (e.g. active vomiting, pneumonia, uncontrolled heart failure);\n* Planned carotid or intracranial revascularization within 3 months;\n* Severe uncontrolled hypertension (systolic blood pressure over 180mmHg or diastolic blood pressure over 100 mmHg);\n* Cardiac insufficiency (NYHA Class ≥II);\n* Pregnant or lactating women;\n* Comorbidity with other serious diseases;\n* Participating in other clinical trials within 3 months;\n* Patients not suitable for the study considered by researcher.","ALL","18 Years",{"count":19,"type":20},600,"ESTIMATED","INTERVENTIONAL",[23],"NA","The effect of head position as a nonpharmacological therapy on acute ischemic stroke (AIS) remains inconclusive. Recent HOPES2 (Head dOwn-Position for acutE moderate ischemic Stroke with large artery atherosclerosis) suggest the safety, feasibility, and potential benefit of the head-down position (HDP) in acute ischemic stroke. The current study aims to investigate the efficacy and safety of HDP in acute moderate ischemic stroke patients with large artery atherosclerosis.",[26],"Stroke, Acute Ischemic","RECRUITING","2026-04-22",{"date":30,"type":31},"2026-04-27","ACTUAL",{"date":33,"type":31},"2024-01-10",{"date":35,"type":20},"2027-10-30",{"name":37,"class":38},"General Hospital of Shenyang Military Region","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100591967","phase-3-intravenous-rhtnk-tpa-before-stroke-thrombectomy-in-the-extended-time-window-100591967","NCT06987305","Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window","Intravenous rhTNK-tPA Versus Placebo Before Endovascular Thrombectomy For Stroke Patient With Large Vessel Occlusion In The Extended Time Window: the BRIDGE-TNK EXTEND Randomized, Placebo-controlled, Double-blind Trial","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Acute ischemic stroke presenting within 4.5-24 hours of last known well;\n3. No significant pre-stroke functional disability: for age \\\u003C80 years, pre-stroke modified Rankin scale (mRS) ≤2; for age ≥80 years, prestroke mRS ≤1;\n4. Baseline NIHSS score ≥5;\n5. Imaging criteria of BOTH:\n\n   1. Occlusion on CTA\u002FMRA in one of the following vessels: M1\u002FM2 segment of middle cerebral artery, A1 segment of anterior cerebral artery, V4 segment of vertebral artery, basilar artery, or P1 segment of posterior cerebral artery. For A1, or P1 occlusions, vessel diameter must be ≥0.75 mm;\n   2. For anterior circulation occlusion: CTP\u002FMRP demonstrating mismatch ratio ≥1.8, absolute mismatch volume ≥15 mL, and ischemic core volume \\\u003C70 mL; OR have a mismatch between the presence of an abnormal signal on MRI diffusion-weighted imaging and no visible signal change on FLAIR. For posterior circulation occlusion: pc-ASPECTS score ≥6.\n6. Plan to received endovascular thrombectomy;\n7. The patient or their legal representative provides written informed consent.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage confirmed by CT\u002FMRI;\n2. Already received intravenous thrombolytic after index stroke.;\n3. Pregnancy or lactation;\n4. Concurrent participation in other investigation drug clinical trials;\n5. Arterial tortuosity or other vascular anomalies precluding endovascular access to target vessel;\n6. Pre-existing neurological\u002Fpsychiatric disorders interfering with neurological assessment;\n7. Space-occupying intracranial tumors (except small meningiomas ≤3 cm);\n8. Intracranial aneurysm or arteriovenous malformation;\n9. Terminal illness with life expectancy \\\u003C6 months;\n10. Anticipated inability to complete follow-up assessments.",{"count":48,"type":20},820,[50],"PHASE3","This randomized, double-blind, placebo-controlled phase III clinical trial aims to evaluate the efficacy and safety of intravenous recombinant human tenecteplase (rhTNK-tPA) in acute ischemic stroke patients with large vessel occlusion presenting 4.5-24 hours after last known well. The study will address two primary questions: 1) Whether rhTNK-tPA enhances pre-thrombectomy reperfusion rates and improves 90-day functional outcomes compared to placebo; 2) Whether rhTNK-tPA increases the risk of symptomatic intracranial hemorrhage and mortality.\n\nParticipants will be randomized to receive either a single bolus of rhTNK-tPA (0.25 mg\u002Fkg, max 25 mg) or matching placebo administered intravenously over 5 seconds. Key assessments include repeat neuroimaging (CT\u002FCTA or MRI\u002FMRA) at 24 hours post-treatment to evaluate reperfusion, NIH Stroke Scale score at day 5-7, and modified Rankin Scale score assessment at 90 days. Safety monitoring will focus on hemorrhagic transformation and mortality events throughout the study period.",[26],[54,55,56],"acute ischemic stroke","endovascular treatment","rhTNK-tPA","2025-12-24",{"date":59,"type":31},"2025-12-31",{"date":61,"type":31},"2025-10-21",{"date":63,"type":20},"2028-02-29",{"name":65,"class":38},"Xinqiao Hospital of Chongqing",4,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100545916","endovascular-treatment-for-extra-large-ischemic-stroke-100545916","NCT06388148","Endovascular Treatment for eXtra-Large Ischemic Stroke","Efficacy and Safety of Endovascular Thrombectomy Plus Medical Management Versus Medical Management Alone in Acute Ischemic Stroke Patients With Large Vessel Occlusion and Extra-Large Infarct Core: A Multicenter, Randomized Controlled Trial","XL STROKE-2","Inclusion Criteria:\n\n1. Age 18 years or older, and modified Rankin scale score = 0 or 1 in patients 80 years or older;\n2. Acute ischemic stroke within 6 hours from last known well to randomization, or with negative MRI-FLAIR (no change on FLAIR sequence and presence of infarct on MRI-DWI) if \\> 6 hours or unknown last known well time;\n3. Occlusion of the internal carotid artery, M1 or M2 segment of the middle cerebral artery confirmed by CTA\u002FMRA\u002FDSA;\n4. Baseline ASPECTS score of 0-2 or infarct core volume ≥100ml;\n5. The patient or patient's representative signs a written informed consent form.\n\nExclusion Criteria:\n\n1. CT or MR evidence of hemorrhage;\n2. Evidence of mass effect with ventricular effacement, midline shift or herniation on baseline imaging;\n3. Vessel tortuosity where it is expected that the thrombectomy device will not be able to reach the occlusion site or result in unstable access;\n4. History of bleeding disorders, severe heart, liver or kidney disease, or sepsis;\n5. Currently participating in another investigational drug study;\n6. Any terminal illness with life expectancy less than 6 months.",{"count":76,"type":20},286,[23],"The role of endovascular thrombectomy in patients with extra-large ischemic burden is still unclear. The XL STROKE-2 randomized trial is aiming to investigate the efficacy and safety of mechanical thrombectomy in acute extra-large ischemic stroke patients with large vessel occlusion.",[26],"2025-12-18",{"date":82,"type":31},"2025-12-26",{"date":84,"type":31},"2024-06-16",{"date":86,"type":20},"2027-01-31",{"name":88,"class":38},"Zhongming Qiu",2,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":102,"conditions":103,"keywords":104,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":39},"100495219","phase-2-intravenous-tirofiban-versus-alteplase-before-mechanical-thrombectomy-in-stroke-100495219","NCT05728333","Intravenous Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Stroke","Intravenous Adjuvant With Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Acute Ischemic Stroke Patients With Large Vessel Occlusion: a Multicenter, Open Label, Randomized Controlled Trial.","ADJUVANT","Inclusion Criteria:\n\n1. Aged 18 years or older.\n2. Presenting with acute ischemic stroke symptom.\n3. Time from onset to hospital arrival:\n\n   * (1) within 4.5 hours\n   * (2) 4.5-9.0 hours, image inclusion criteria for the EXTEND trial must be met\n   * (3) \\> 4.5 hours but within 24 hours, image inclusion criteria for the WAKE-UP trial must be met.\n4. Eligible for intravenous thrombolysis.\n5. Occlusion of the internal carotid artery, M1 or M2 segment of the middle cerebral artery, vertebrobasilar artery confirmed by CTA, MRA, or DSA.\n6. Informed consent obtained from patients or their legal representatives.\n\nExclusion Criteria:\n\n1. CT or MR evidence of hemorrhage (the presence of micro-bleeds is allowed);\n2. Contraindications of IV rt-PA or tirofiban;\n3. Contraindication to radiographic contrast agents, nickel, titanium metals or their alloys;\n4. Arterial tortuosity and\u002For other arterial disease that would prevent the device from reaching the target vessel;\n5. Patients with a preexisting neurological or psychiatric disease that would confound the neurological functional evaluations;\n6. CT or MRI evidence of mass effect or intracranial tumor (except small eningioma);\n7. CT or MRI evidence of cerebral vasculitis;\n8. CTA or MRA evidence of intracranial arteriovenous malformations or aneurysms;\n9. Any terminal illness with life expectancy less than 6 months.",{"count":99,"type":20},800,[101,50],"PHASE2","In patients with acute ischemic stroke secondary to large vessel occlusion, the role of intravenous adjunctive medications, such as tirofiban, or alteplase before endovascular thrombectomy has not been well investigated. This trial aim to evaluate the efficacy and safety of intravenous tirofiban versus alteplase for acute ischemic stroke patients with large vessel occlusion piror to endovascular thrombectomy.",[26],[105,106,107,108],"endovascular thrombectomy","large vessel occlusion","intravenous thrombolysis","tirofiban",{"date":82,"type":31},{"date":111,"type":31},"2023-11-28",{"date":113,"type":20},"2026-07-31",{"name":65,"class":38},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":124,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":39},"100552380","intracranial-atherosclerosis-related-large-vessel-occlusion-treated-with-urgent-stenting-icarus-100552380","NCT06472336","IntraCranial Atherosclerosis Related Large-vessel Occlusion Treated With Urgent Stenting (ICARUS)","IntraCranial Atherosclerosis Related Large-vessel Occlusion Treated With Urgent Stenting - a Pragmatic, International, Multicentre, Randomized Trial","Inclusion Criteria:\n\n* A relevant clinical deficit defined as a National Institute of Health Stoke Scale (NIHSS) Score of ≥ 6 points for anterior circulation stroke and a NIHSS Score of ≥ 10 for posterior circulation stroke\n* Anticipated randomization within 24 hours of last seen well (LSW)\n* Occlusion of the Internal Carotid Artery, the M1 segment, the proximal\u002Fdominant M2 segment of the Middle Cerebral Artery, the Basilar Artery or the V4 segment of the Vertebral Artery\n* Absence of recanalization (thrombolysis in myocardial infarction score of 0 or 1) after up to three endovascular treatment passes\n* High probability of underlying intracranial atherosclerotic disease based on the assessment of the treating physician\n* Age ≥ 18 years\n* Occluded artery amendable to stenting by judgement of the treating physician\n* Absence of a large infarct core defined as (posterior circulation) Alberta Stroke Program Early CT Score of 6 or above\n* Informed Consent as documented by signature or fulfilling the criteria for emergency consent procedures\n\nExclusion Criteria:\n\n* Acute intracranial haemorrhage\n* Pre-stroke modified Rankin Scale score of 3 or above\n* Known, severe comorbidities, which will likely prevent improvement or follow-up (cancer, alcohol\u002Fdrug abuse or dementia)\n* Known clotting disease or suspicion of underlying disease which might lead to a hyper coagulant state\n* In-hospital Stroke\n* Known contraindications for anti-platelet therapy\n* Known (serious) sensitivity to radiographic contrast agents, nickel, titanium metals or their alloys\n* Foreseeable difficulties in follow-up due to geographic reasons (e.g., patients living abroad)\n* Evidence of an ongoing pregnancy prior to randomization\n* Radiological confirmed evidence of mass effect or intracranial tumour (except small meningioma)\n* Radiological confirmed evidence of cerebral vasculitis\n* Evidence of vessel recanalization prior to randomisation\n* Participation in another interventional trial which could confound the primary endpoint",{"count":123,"type":20},498,[23],"The goal of this international, multi-center, randomized clinical trial is to compare two treatment options, early intracranial stenting and continued stent-retriever or aspiration based endovascular treatment, for stroke patients with a large vessel occlusion, who experienced failure of recanalisation after initial treatment due to intracranial atherosclerosis.",[127,26,128],"Stroke","Intracranial Atherosclerosis",[130,131],"Endovascular Treatment","Intracranial Stenting","2025-12-09",{"date":134,"type":31},"2025-12-17",{"date":136,"type":31},"2025-03-31",{"date":138,"type":20},"2027-08",{"name":140,"class":38},"University Hospital, Basel, Switzerland",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":148,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":163,"locationsCount":4},"100612358","phase-3-isosorbide-mononitrate-and-butylphthalide-to-reduce-the-risk-of-disability-in-patients-with-acute-lacunar-stroke-impact-100612358","NCT07252544","Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)","Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke: a 2×2 Factorial Randomized Controlled Trial (IMPACT)","Inclusion Criteria:\n\n1. Age ≥ 30 years;\n2. Clinical lacunar syndrome within 7 days;\n3. Brain CT\u002FMRI after symptom onset:\n\n   1. a relevant (in time and location) acute lacunar infarct;\n   2. if no relevant lesion, symptom duration \\>24 hours, with no other suspected stroke etiologies (such as cerebral hemorrhage, cortical infarction, seizures, etc.)\n4. MoCA score meeting the following criteria:\n\n   1. MoCA ≥ 13 if educated ≤ 6 years;\n   2. MoCA ≥ 15 if 7 ≤ educated ≤ 12 years;\n   3. MoCA ≥ 18 if educated ≥ 13 years；\n5. mRS ≤ 1 prior to this episode;\n6. Patient or a legally authorized representative signed informed consent.\n\nExclusion Criteria:\n\n1. Ischemic stroke of large artery atherosclerosis, cardioembolism, or other etiologies (TOAST classification);\n2. Diagnosed or suspected hereditary CSVD;\n3. Intracerebral hemorrhage within the past 3 months including parenchymal, intraventricular, subarachnoid hemorrhage, subdural\u002Fepidural hematoma;\n4. Neurodegenerative diseases or systemic diseases that may lead to cognitive impairment, such as Alzheimer's disease, mixed dementia, Parkinson's disease, systemic autoimmune diseases, hepatic encephalopathy, or uremic encephalopathy.\n5. Previously diagnosed psychiatric disorders (DSM-5 criteria).\n6. Other active neurological disorders (e.g., recurrent seizures, brain tumors, vascular malformations, untreated aneurysms \\>3 mm).\n7. Hypotension (seated systolic blood pressure \\\u003C100 mmHg), bradycardia (heart rate \\\u003C60 bpm), sick sinus syndrome or severe cardiopulmonary disease.\n8. History of congestive heart failure, acute myocardial infarction or other severe cardiac dysfunctions (NYHA Class III-IV).\n9. Coagulation disorders, bleeding tendency or systemic bleeding, including but not limited to prothrombin time \\>3×upper limit of normal (ULN), platelet count \\\u003C50×109\u002FL, hemophilia, capillary fragility, gastrointestinal bleeding, urinary tract bleeding, hemoptysis, or vitreous hemorrhage, etc.\n10. Severe hepatic or renal insufficiency (note: severe hepatic insufficiency is defined as ALT or AST \\> 3×ULN or acute hepatitis, chronic active hepatitis, cirrhosis; severe renal insufficiency is defined as eGFR \\\u003C 45 ml\u002Fmin\u002F1.73m², creatinine clearance \\\u003C 40 ml\u002Fmin, or known chronic kidney disease of stage 3 or higher).\n11. Head trauma, intracranial or spinal surgery, major surgical procedures or severe trauma within the past 4 weeks.\n12. ISMN or NBP use within the past 3 days.\n13. Have contraindications to ISMN or NBP, or allergy to their components.\n14. Have to use the contraindicated drugs of this trial for a long time.\n15. Pregnant, breastfeeding or planning to pregnant during this study.\n16. Unable to tolerate MRI or with MRI contraindications.\n17. Have severe diseases or expected survival \\\u003C12 months.\n18. Participate in other clinical trials within 30 days before this trial.\n19. Unlikely to comply with study procedures and follow-up procedures for whatever reason in the opinion of the research physician.","30 Years",{"count":150,"type":20},3156,[50],"The goal of this multicenter, double-blind, 2×2 factorial randomized controlled trial is to evaluate the efficacy and safety of isosorbide mononitrate, butylphthalide, and their combination in reducing disability in patients with acute lacunar stroke.",[154,26,155],"Stroke, Lacunar","Cerebral Small Vessel Diseases","NOT_YET_RECRUITING","2025-11-24",{"date":159,"type":31},"2025-11-26",{"date":161,"type":20},"2025-12-01",{"date":63,"type":20},{"name":164,"class":38},"Beijing Tiantan Hospital",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":178,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":39},"100594239","early-endovascular-treatment-in-isolated-internal-carotid-artery-occlusion-100594239","NCT07016854","Early Endovascular Treatment in Isolated Internal Carotid Artery Occlusion","Evaluation of Early Endovascular Treatment in Acute Ischemic Stroke With Isolated Internal Carotid Artery Occlusion (EVT-iICAO)","EVT-iICAO","Inclusion Criteria:\n\n1. Age ≥18.\n2. Clinical signs consistent with an acute ischemic stroke and randomization no later than 23 hours after the time last known to be well.\n3. CTP, CTA or enhanced MRA within 1 hour before randomization showed that the offending vessel was isolated internal carotid artery occlusion, namely occlusion of C1-C6 segments (according to Bouthillier's segmentation) at any location. There was no ipsilateral intracranial branch occlusion (T or L shape of internal carotid artery, M1 or M2 segment of middle cerebral artery, A1 or A2 segment of anterior cerebral artery, P1 or P2 segment of posterior cerebral artery).\n4. Neurological deficit with a NIHSS of \\>5, or ≤5 points with disabling symptoms (complete hemianopsia, severe aphasia, neglect, any limb weakness that cannot sustain resistance to gravity, and functional loss that is considered by doctors and patients to be potentially disabling by clinical evaluation).\n5. Mismatch: target Mismatch Profile on CT perfusion or MRI (ischemic core volume is \\\u003C 70 ml, mismatch ratio is ≥1.8 and mismatch volume is ≥15 ml); clinical-imaging mismatch defined as an ASPECTS score of more than 5, was present if perfusion data were not available or imaging quality was poor enough to be interpreted.\n6. mRS Score before stroke ≤2.\n7. Patient\u002FLegally Authorized Representative has signed the Informed Consent form.\n\nExclusion Criteria:\n\n1. The patient underwent carotid endarterectomy within 1 month.\n2. Severe comorbid condition with life expectancy less than 6 months at baseline.\n3. Other suspected cerebrovascular diseases (vasculitis, untreated cerebrovascular malformation, intracranial aneurysm, etc.) based on history and CTA\u002FMRA.\n4. Women who are pregnant or planning to become pregnant at the time of the study and who are known to be pregnant or breastfeeding at the time of admission.\n5. Known life-threatening allergic reactions to contrast media or intravascular products.\n6. Chronic internal carotid artery occlusion, defined as known carotid artery occlusion (imaging examination) ≥30 days before randomization or highly suspected chronic internal carotid artery occlusion based on medical history and CT\u002FMRI.\n7. Tandem occlusion, which was defined as internal carotid artery occlusion combined with large intracranial vessel occlusion (T or L shape of internal carotid artery, M1 or M2 segment of middle cerebral artery, A1 or A2 segment of anterior cerebral artery, P1 or P2 segment of posterior cerebral artery).\n8. No known vascular access.\n9. Suspected aortic dissection based on medical history, clinical evaluation or\u002Fand imaging.\n10. Evidence of intracranial hemorrhage on CT\u002FMRI.\n11. Patient unable to come or unavailable for follow-up.\n12. Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations.\n13. Seizures at stroke onset if they make the diagnosis of stroke doubtful and preclude obtaining an accurate baseline NIHSS assessment.\n14. Patients have contraindications to the use of heparin and antiplatelet drugs.",{"count":174,"type":20},140,[23],"The primary hypothesis being tested in this trial is that acute ischemic stroke with isolated internal carotid artery occlusion will have improved clinical outcomes when given early endovascular treatment compared with that of given best medical treatment.",[26],[55,179],"isolated internal carotid artery occlusion","2025-06-10",{"date":182,"type":31},"2025-06-12",{"date":184,"type":20},"2025-06",{"date":186,"type":20},"2027-12-31",{"name":188,"class":38},"Sir Run Run Shaw Hospital",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":21,"phases":199,"briefSummary":200,"conditions":201,"keywords":202,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":39},"100575119","phase-3-intra-arterial-thrombolysis-after-successful-reperfusion-in-anterior-circulation-ischemic-stroke-100575119","NCT06768138","Intra-Arterial Thrombolysis After SUCCESSful Reperfusion in Anterior Circulation Ischemic Stroke","Intra-Arterial Thrombolysis After SUCCESSful Angiographic Recanalization in Acute Large Vessel Occlusion Stroke of the Anterior Circulation: the IA-SUCCESS Multicenter, Randomized Clinical Trial","IA-SUCCESS","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Pre-stroke mRS 0-2\n* Acute ischemic stroke with anterior circulation large vessel occlusion defined as intracranial internal carotid artery, M1, or M2 occlusion proven on CT or MRI\n* NIHSS score ≥ 5 at admission\n* Acute reperfusion strategy started within 24h after stroke onset according to the international guidelines\n* DWI-ASPECTS ≥ 2 (MRI) or CT-ASPECTS ≥ 3\n* Delay from imaging to puncture within 3 hours for transferred patients\n* eTICI 2b-2c-3 after intravenous thrombolysis alone, bridging therapy, or mechanical thrombectomy alone and confirmed by catheter angiogram\n* Person affiliated to or beneficiary of a social security plan\n\nExclusion Criteria:\n\n* Person who do not speak French\n* Contraindications for intra-arterial thrombolysis: Platelet count \\\u003C100 000\u002Fmm3, INR \\>1.7, AOD use \\\u003C48h or biological confirmation of activity and effective heparin treatment\n* Bleeding-risk complications during the mechanical thrombectomy procedure (e.g carotid dissection, complicated femoral approach)\n* Bleeding-risk complications consecutive to a fall associated with stroke\n* More than 5 thrombectomy device\n* Intracerebral hemorrhage\n* Occlusion or high grade stenosis treated by stenting\n* Patient expected to be unable to present or be available for 3-month visit follow-up\n* Participation in another clinical trial within 30 days prior to the inclusion which the experiment may affect the 90-day mRS score\n* Woman of childbearing age without effective contraception\n* Person referred in articles L.1121-5, L. 1121-7 and L.1121-8 of the French Public Health Code",{"count":198,"type":20},626,[50],"Stroke is a leading cause of disability and mortality worldwide. Despite the clinical benefit of mechanical thrombectomy, 1 out of 2 patients treated are functionally independent at 90 days. Achieving the best possible angiographic reperfusion is a key determinant of clinical outcome in acute ischemic stroke patients with anterior circulation large vessel occlusion. Mechanical thrombectomy is standard treatment for large vessel occlusion stroke patients within 24. In the setting of successful (eTICI ≥2b), adjunct intra-arterial thrombolysis may be a promising therapeutic option allowing recanalization of distal arterial occlusions (not accessible to mechanical devices) and improvement of upstream brain reperfusion by targeting microvascular obstruction.\n\nThe IA-SUCCESS randomized trial aims to assess the clinical and safety of adjunct intra-arterial thrombolysis vs. no adjunct intra-arterial thrombolysis after successful angiographic reperfusion in patients with acute anterior circulation large vessel occlusion stroke.",[26],[203,204,205,206,207,208],"Ischemic stroke","Thrombectomy","Endovascular treatment","Intra-arterial thrombolysis","Randomized controlled trial","Recanalisation","2025-06-03",{"date":211,"type":31},"2025-06-05",{"date":213,"type":31},"2025-06-01",{"date":215,"type":20},"2029-07-01",{"name":217,"class":38},"Central Hospital, Nancy, France",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":21,"phases":228,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":89},"100549712","immediate-angioplasty-for-acute-ischemic-stroke-with-severe-intracranial-atherosclerotic-stenosis-100549712","NCT06437600","Immediate Angioplasty For Acute Ischemic Stroke With Severe Intracranial Atherosclerotic Stenosis","Immediate Angioplasty For Acute Ischemic Stroke With Severe Intracranial Atherosclerotic Stenosis (MAGIC): A Multicenter, Prospective, Open-label, Blinded Endpoint, Randomized Controlled Trial","MAGIC","Inclusion Criteria:\n\n1. Aged 18 years or older.\n2. Diagnosed with AIS and baseline NIHSS ≥6.\n3. Pre-stroke mRS ≤2.\n4. Time from symptom onset to randomization ≤ 24 hours; the onset time refers to \"Last Known Well\" (LKW).\n5. Non-contrast CT ASPECTS score ≥6.\n6. CTA confirmed severe ICAS (70-99%) of the intracranial segment of the internal carotid artery, or M1 or M2 segment of the middle cerebral artery, and is presumed to be responsible for the stroke.\n7. Informed consent signed by the patient or authorized representative.\n\nExclusion Criteria:\n\n1. Normal diameter of the culprit vessel \\\u003C2.0 mm.\n2. Isolated perforator artery infarction (except for combined cortical hypoperfusion).\n3. Hemorrhagic stroke within the past 90 days.\n4. Cerebrovascular conditions such as vasculitis, moya-moya disease, arterial inflammatory stenosis, vasospasm, traumatic dissection, etc..\n5. Severe calcification at the stenosis site, where expected residual stenosis ≤50% cannot be achieved with procedure.\n6. Known cardiac thrombus source (e.g., atrial fibrillation, patent foramen ovale, infective endocarditis).\n7. INR \\>1.7 when using warfarin; coagulation dysfunction or uncorrectable bleeding factors.\n8. Platelet count \\\u003C50×10\\^9\u002FL.\n9. Intracranial hemorrhage confirmed by CT or MRI.\n10. Women who are pregnant or breastfeeding.\n11. Participation in other intervention clinical trials.\n12. Known severe renal insufficiency with glomerular filtration rate \\\u003C30 ml\u002Fmin or blood creatinine \\>220 μmol\u002FL (2.5 mg\u002Fdl).\n13. Severe allergy to contrast (non-mild rash allergy) or absolute contraindication to iodine contrast.\n14. Aortic dissection.\n15. Concomitant intracranial tumor (except for meningioma \\\u003C10mm) or arteriovenous malformation.\n16. Severe vascular tortuosity, difficult access for intervention, or inability to complete endovascular treatment.\n17. Any active bleeding or recent bleeding in the last 1 month.\n18. SBP\\>185 mmHg or DBP\\>110 mmHg refractory to treatment.\n19. Anticipated life expectancy \\\u003C3 months (e.g., malignancy, severe cardiopulmonary disease, etc.).\n20. Any condition that, in the judgment of the investigator, makes the patient unsuitable for this study or where this study may impose a significant risk to the patient (e.g., inability to understand and\u002For comply with study procedures and\u002For follow-up due to psychiatric disorders, cognitive or emotional impairment).",{"count":227,"type":20},412,[23],"A multicenter, prospective, open-label, blinded endpoint, randomized controlled trial that aims to evaluate the effect of immediate angioplasty (with or without stenting) for acute ischemic stroke (AIS) with severe intracranial atherosclerotic stenosis (ICAS) in improving the 90-day functional outcome.",[26],"2025-05-20",{"date":233,"type":31},"2025-05-25",{"date":235,"type":31},"2025-05-08",{"date":237,"type":20},"2029-12",{"name":239,"class":38},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":21,"phases":251,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":271},"100544882","the-efficacy-and-safety-of-y-3-intracalvariosseous-injection-versus-intravenous-injection-in-the-treatment-of-acute-large-hemispheric-infarction-100544882","NCT06374667","The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction","The Efficacy and Safety of Y-3 Intracalvariosseous Injection Bypassing Blood-brain Barrier Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction（SOLUTION-2）","SOLUTION-2","Inclusion Criteria:\n\n* 18≤Age≤80 years;\n* First stroke or complete self-care before the onset of current stroke (mRS 0-1);\n* Administration of drugs can be completed within 24h of the onset of signs and symptoms of neurological deficits (in patients with wake-up strokes or unwitnessed strokes, the time of onset is defined as the time of last normal presentation);\n* Clinical symptoms, signs and imaging diagnosis of cerebral infarction in the area supplied by the middle cerebral artery, together with the following features:\n\n  1. 16≤ NIHSS ≤32 points, and the sum of the scores of motor arm and motor leg is ≥6;\n  2. Imaging suggestive of core infarct area: apparent diffusion coefficient (ADC) values \\\u003C620×10\\^-6mm\\^2\u002Fs lesion volume on magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI) sequences or cerebral blood flow (CBF) \\\u003C30% of volume 70-300 ml on computed tomography perfusion imaging (CTP) or an Alberta Stroke Program Early CT Score (ASPECTS) of 0-6, with inconsistent findings, the investigator is required to make a reasoned judgement by taking into account all the information (scanning time, the imaging method that best responds to the size of infarct, etc.) and record it.\n* NIHSS score not improving or progressing after reperfusion therapy and total score still ≤32.\n* Informed consent signed\n\nExclusion Criteria:\n\n* Complications with other cerebrovascular diseases meet one of the following conditions:\n\n  1. Complicated with acute cerebral hemorrhage and subarachnoid hemorrhage;\n  2. Complicated with acute posterior circulation cerebral infarction or severe posterior circulation stenosis (\\>70%);\n  3. Or imaging suggests that the area of cerebral infarction is involved bilaterally;\n  4. The cause of the TOAST classification was considered as intracranial artery dissection, vasculitis, moyamoya disease and other etiological types.\n* Hemorrhage transformation in the infarction area, hematoma area ≥30% of the infarction area, and has obvious space-occupying effect;\n* Presence of clinical signs of brain herniation formation, e.g., unilateral or bilateral pupil dilation and fixation; cerebral oedema-associated loss of consciousness (NIHSS 1a \\> 2 points), or other loss of brainstem reflexes in the judgement of the investigator, caused by cerebral oedema or cerebral herniation formation; or other signs of instability of vital signs that are difficult to control;\n* Craniotomy decompression was planned before randomization;\n* Refractory hypertension (systolic \\> 200mmHg or diastolic \\> 110mmHg) or hypotension (systolic \\\u003C 70mmHg or diastolic \\\u003C 50mmHg) that is difficult to control with medication;\n* Abnormal blood glucose before randomization (random venous blood glucose \\\u003C 2.8mmol\u002FL or \\> 23mmol\u002FL);\n* Presence of significant abnormal liver function markers or renal function markers prior to randomization;\n* Note: Severe liver function abnormalities were defined as serum alanine aminotransferase (ALT), or aspartate aminotransferase (AST) \\> 3 times the upper limit of normal (ULN). Significant renal insufficiency is defined as eGFR less than 60 mL\u002Fmin\u002F1.73 m² (eGFR, calculated using the CKD-EPI formula)\n* Acute ST-elevation myocardial infarction (MI) and\u002For decompensated heart failure (meeting the New York College of Cardiology (NYHA) Heart function grades III and IV) within the past 3 months;\n* Presence of contraindications to intracalvariosseous injection, e.g., skull fracture in the last 3 months, skull infection, subdural\u002Fextradural hematoma, subcutaneous hematoma, skin or subcutaneous infection of the scalp, poorly displayed skull bone marrow niches；\n* Bleeding tendencies considered by the investigators to be detrimental to the procedure include, but are not limited to, platelet counts \\\u003C 100×10\\^9\u002FL, and the presence of clotting disorders such as hemophilia；\n* Presence of severe or very severe anemia (hemoglobin \\\u003C60 g\u002FL) at randomization；\n* Patients with severe respiratory diseases (severe chronic obstructive pulmonary disease, respiratory failure, etc.) should be corrected by intubation, tracheotomy, or ventilator;\n* The subjects were considered to have developed clinically significant serious infections, including severe local infections or systemic infections;\n* Diagnosed severe degenerative diseases of the central nervous system such as Alzheimer's Disease (AD), Parkinson's Disease (PD), and severe dementia of all causes, or psychiatric disorders (e.g., schizophrenia, depression, etc.);\n* Subjects with a life expectancy of less than 3 months due to conditions not considered current by the investigators, such as tumors;\n* Known allergy to any component of investigational process therapy drugs and contrast agents;\n* Subjects who are pregnant, breastfeeding or have the possibility of becoming pregnant or plan to become pregnant;\n* Subjects are unable to comply with trial protocols or follow-up requirements;\n* Other circumstances deemed by the investigators to be unsuitable for enrollment (registration of reasons for inability to enroll is required);\n* Have participated in other interventional clinical trials.","80 Years",{"count":250,"type":20},134,[23],"A pilot study confirmed the feasibility and safety of neuroprotectant Y-3 intracalvariosseous(ICO) injection in patients with malignant middle cerebral artery infarction (mMCAI), showing a trend in improving 90-day functional scores compared to conventional treatment. The aim of this trial is to further investigate the efficacy and safety of ICO injection of Y-3 compared to intravenous injection in patients with acute large hemispheric infarction(LHI) who has contraindications of reperfusion therapy or have got poor reperfusion therapy outcomes.",[26,254],"Blood-Brain Barrier",[256,257,258,259,260,261],"large hemispheric infarction","Y-3","postsynaptic density protein 95 inhibitor","BBB-bypassing route","brain drug delivery","intracalvariosseous injection","2025-01-24",{"date":264,"type":31},"2025-01-28",{"date":266,"type":31},"2024-04-22",{"date":268,"type":20},"2027-03-15",{"name":270,"class":38},"yilong Wang",6,{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":248,"enrollmentInfo":279,"targetDuration":4,"studyType":21,"phases":281,"briefSummary":282,"conditions":283,"keywords":289,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":39},"100573955","research-on-the-effectiveness-of-neurorehabilitation-after-stroke-100573955","NCT06753006","Research on the Effectiveness of Neurorehabilitation After Stroke","A Study of Neurorehabilitation Based on Robotics, Brain-Computer Interface (BCI) and Virtual Reality (VR) in Patients with Upper Limb Paresis Due to Stroke in the Early Rehabilitation Period","Inclusion Criteria:\n\n* Signed written informed consent.\n* Age 18 to 80 years at the time of stroke onset.\n* Early rehabilitation period (up to 6 months post-stroke).\n* Diagnosis of acute cerebrovascular accident confirmed by MRI or CT.\n* Upper limb paresis severity between 0 and 3 on the 6-point Medical Research Council (MRC) muscle strength scale.\n* Ability and willingness to comply with the study protocol.\n* Demonstrated motivation for rehabilitation.\n\nExclusion Criteria:\n\n* Montreal Cognitive Assessment scale (MoCA) score less than 10 points.\n* Hamilton Depression Rating Scale (Ham-D) score greater than 18 points.\n* Modified Rankin Scale (mRS) score greater than 4 points.\n* Pre-existing conditions that cause decreased muscle strength or increased muscle tone in the upper limbs (e.g., cerebral palsy, traumatic brain injury) or rigidity (e.g., Parkinson's disease, contractures).\n* Advanced arthritis or significant limitation of upper limb range of motion.\n* Absence of part of the upper limb due to amputation for any reason.\n* Any medical condition that may affect the conduct of the study or patient safety (e.g., mental illness).\n* Alcohol abuse or recreational drug use within the 12 months preceding the study.\n* Use of experimental medications or medical devices within the 30 days preceding the study.\n* Inability to comply with research procedures, as determined by the researcher.\n* The severity of the patient's condition, based on neurological or physical status, does not permit full rehabilitation.\n* Visual acuity less than 0.2 in the weakest eye according to the Sivtsev visual acuity chart.\n* Unstable angina and\u002For heart attack within the 30 days preceding the study.\n* Recurrent stroke.\n* Uncontrolled arterial hypertension.\n* Ataxia.\n* Presence of a pacemaker and\u002For other implanted electronic devices.\n* Use of muscle relaxants.\n* Peripheral neuropathy.\n* Coexisting diseases in an exacerbation or decompensated stage requiring active treatment.\n* Allergic reactions or other skin lesions at the EEG electrode application sites at the time of the study.\n* Acute urinary tract infections.\n* Acute thrombophlebitis.\n* Any form of epilepsy.\n* Benign and malignant neoplasms.",{"count":280,"type":20},44,[23],"This clinical trial aims to investigate the effectiveness of a novel neurorehabilitation technology for treating stroke in adults. The study will evaluate a simulator that combines robotic orthosis, a non-invasive brain-computer interface (BCI), and a virtual reality (VR) display. The goal of this trial is to advance stroke rehabilitation by exploring the potential benefits of these cutting-edge technologies.\n\nKey Research Questions:\n\nEfficacy: Does the new simulator significantly improve arm function compared to standard rehabilitation techniques?\n\nBCI Technology: Which approach - motor imagery of only the paretic arm or both the paretic and healthy arm - yields greater functional improvements?\n\nVR Contribution: How does the integration of VR enhance rehabilitation outcomes?\n\nSafety and Tolerability: What potential side effects or adverse events may arise from using the new simulator?\n\nParticipants who have suffered a stroke will undergo a standard rehabilitation course, during which 10-12 sessions will take place using the innovative simulator: a robotic device moves a patient's paralyzed arm at the command of a non-invasive brain-computer interface to perform a game task resembling real-life activities, augmented by a virtual reality display.\n\nResearchers will assess the impact of the new technology on arm function to determine its efficacy in promoting recovery.",[127,284,285,286,287,288],"Stroke Acute","Stroke with Hemiparesis","Stroke, Acute","Stroke, Acute, Ischemic","Stroke, Ischemic",[127,290,291,292,293,294,295],"Rehabilitation","Brain-Computer Interface","Motor Imagery","Robotics","Virtual Reality","Neurofeedback","2024-12-31",{"date":298,"type":31},"2025-01-01",{"date":300,"type":31},"2024-08-27",{"date":302,"type":20},"2025-07",{"name":304,"class":305},"Neurotechnika","INDUSTRY",{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":316,"phases":4,"briefSummary":317,"conditions":318,"keywords":319,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":89},"100569206","perfusion-post-thrombectomy-prophet-100569206","NCT06691230","PeRfusiOn Post tHrombEcTomy (PROPHET)","PeRfusiOn Post tHrombEcTomy (PROPHET) A Prospective Observational Cohort Study","PROPHET","Inclusion Criteria:\n\n* Informed consent as documented by a signature\n* The patients received mechanical thrombectomy or there was the intention to perform endovascular treatment, but only diagnostic angiography was performed.\n* Patients received FDCTP as clinically indicated by the treating physician.\n\nExclusion Criteria:\n\n* Inability to give consent due to insufficient knowledge of the project language\n* Inability to follow the clinically indicated visit at 90 days after the index stroke (e.g. patients living abroad).",{"count":315,"type":20},279,"OBSERVATIONAL","Endovascular mechanical thrombectomy is the standard of care for treating patients with a large-vessel occlusion acute ischemic stroke. However, in more than half of these patients, remaining distal vessel occlusions limit the benefit of this therapy. Currently the detection of residual vessel occlusions and the decision for further treatment by the operator is based on the 2D digital subtraction angiography (DSA) images. However, this technique has several limitations. Recently, a new imaging technique, with the possibility to acquire 3D time-resolved perfusion images directly in the operating room was introduced (the flat-panel detector computed tomography perfusion imaging, FDCTP). It can overcome the spatial limitations of 2D DSA, but the details on clinical validation and utility of FDCTP are currently lacking.",[287],[320,321,322,323,324],"Acute ischemic stroke","Large-vessel occlusion","Endovascular mechanical thrombectomy","Flat-panel detector computed tomography perfusion imaging","Perfusion imaging","2024-11-13",{"date":327,"type":31},"2024-11-15",{"date":329,"type":31},"2024-11-01",{"date":331,"type":20},"2028-02-28",{"name":333,"class":38},"Insel Gruppe AG, University Hospital Bern",{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":21,"phases":344,"briefSummary":345,"conditions":346,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":89},"100505092","phase-3-intra-arterial-alteplase-for-acute-ischemic-stroke-after-mechanical-thrombectomy-100505092","NCT05856851","Intra-arterial Alteplase for Acute Ischemic Stroke After Mechanical Thrombectomy","Intra-arterial Alteplase for Acute Ischemic Stroke After Mechanical Thrombectomy (PEARL): A Multicenter, Prospective, Open-label, Blinded Endpoint, Randomized Controlled Trial","PEARL","Inclusion Criteria:\n\n1. Aged 18 years or older.\n2. Clinical diagnosis of acute ischemic stroke.\n3. Time from symptom onset to randomization within 24 hours, including wake-up stroke or no-witness stroke; the onset time refers to \"Last Known Well\" (LKW).\n4. CTA or MRA confirmed occlusion of the intracranial segment of the internal carotid artery, or M1 or M2 segment of the middle cerebral artery; stable eTICI score of 2b50-3 after mechanical thrombectomy, with or without intravenous thrombolysis. Patients with an eTICI score of 2b50-3 on the diagnostic cerebral angiography before mechanical thrombectomy are also eligible for the study.\n5. Baseline NIHSS of 6-25.\n6. NCCT\u002FDWI-MRI ASPECTS ≥ 6;\n7. Pre-stroke mRS score ≤ 1, or mRS \\>1 but not related to neurological disease (e.g., amputation, blindness).\n8. Signed informed consent.\n\nExclusion Criteria:\n\n1. Contraindication to rt-PA (except time to therapy).\n2. Planned use of dual antiplatelet therapy within the first 24 hours after mechanical thrombectomy.\n3. Angiographic evaluation showing dissection, severe stenosis, or complete occlusion of the carotid artery, which requires the use of carotid artery stents during the endovascular procedure.\n4. Suspected cerebral vasculitis based on medical history and\u002For angiographic evaluation.\n5. Women who are pregnant or breastfeeding.\n6. Participation in other clinical trials.\n7. Preoperative intracranial hemorrhage confirmed by cranial CT or MRI.\n8. Known genetic or acquired bleeding disposition with anticoagulation factor deficiency.\n9. Coagulation disorder with INR \\> 1.7 or use of new oral anticoagulants (within 48 hours of symptom onset).\n10. Platelet count \\\u003C50X10\\^9\u002FL.\n11. Suspected vascular occlusion as a result of infective endocarditis.\n12. Known severe renal insufficiency with glomerular filtration rate \\\u003C30 ml\u002Fmin or blood creatinine \\>220 μmol\u002FL (2.5 mg\u002Fdl).\n13. Severe allergy to contrast (non-mild rash allergy) or absolute contraindication to iodine contrast.\n14. Suspected aortic dissection.\n15. Previous parenchymal organ surgery or biopsy in the last 1 month;\n16. Any active bleeding or recent bleeding (gastrointestinal, urinary tract bleeding, etc.) in the last 1 month;\n17. SBP \\> 185 mmHg or DBP \\> 110 mmHg refractory to treatment.\n18. Anticipated life expectancy \\\u003C 6 months (e.g., malignancy, severe cardiopulmonary disease, etc.).\n19. Any condition that, in the judgment of the investigator, makes the patient unsuitable for this study or where this study may impose a significant risk to the patient (e.g., inability to understand and\u002For comply with study procedures and\u002For follow-up due to psychiatric disorders, cognitive or emotional impairment).",{"count":343,"type":20},324,[50],"A multicenter, prospective, open-label, blinded endpoint, randomized controlled trial aiming at evaluating the efficacy and safety of intra-arterial recombinant human tissue plasminogen activator (rt-PA) after successful recanalization of acute large vessel occlusion in the anterior circulation by mechanical thrombectomy in improving the 90-day functional outcome.",[26],"2024-08-29",{"date":349,"type":31},"2024-09-03",{"date":351,"type":31},"2023-08-01",{"date":353,"type":20},"2025-12",{"name":239,"class":38},{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":21,"phases":365,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":4},"100544757","phase-2-tirofiban-for-successful-endovascular-stroke-thrombectomy-100544757","NCT06373042","Tirofiban for Successful Endovascular Stroke Thrombectomy","Efficacy and Safety of Tirofiban Versus Placebo After Successful Reperfusion With Endovascular Thrombectomy in Acute Ischemic Stroke Patients With Anterior Circulation Large Vessel Occlusion: a Multicenter, Double-Blind, Randomized Clinical Trial","ADJUVANT-2","Inclusion Criteria:\n\n* Clinical inclusion criteria\n\n  1. Aged 18 years or older;\n  2. Acute ischemic stroke within 24 hours from last known well to randomization;\n  3. NIHSS score ≥6 and \\\u003C30 points at baseline;\n  4. Written informed consent is obtained from patients and\u002For their legal representatives.\n* Imaging inclusion criteria\n\n  1. CTA\u002FMRA\u002FDSA showed occlusion of the internal carotid artery, middle cerebral artery M1 or M2 segment;\n  2. For patients within 6 hours from last known well to randomization, ASPECTS 3-10 or infarct volume ≤100ml; 6-24 hours, ASPECTS 6-10 or infarct volume ≤70ml or DWI-FLAIR mismatch;\n  3. Treated with endovascular thrombectomy and achieved successful reperfusion (defined as eTICI grade 2b50 or higher).\n\nExclusion Criteria:\n\n1. Cardiogenic embolism;\n2. Patient receive tirofiban for angioplasty\u002Fstenting prior to randomization;\n3. Intracranial hemorrhage confirmed by flat panel CT on angiography machine prior to randomization;\n4. Patients who are on prior anticoagulant therapy, e.g. for deep venous thrombosis or pulmonary embolism or mechanical heart valve;\n5. Routine blood test platelet count less than 100×10⁹\u002FL;\n6. Renal insufficiency, glomerular filtration rate \\\u003C 60 mL\u002Fmin;\n7. Pregnant or lactating women;\n8. Allergy to tirofiban, contrast agent, nickel, titanium or its alloys;\n9. History of neurological or psychiatric illness that precludes the assessment of neurological function;\n10. History of bleeding disorder, severe heart, liver or kidney disease, or sepsis;\n11. Any terminal illness with life expectancy less than 6 months;\n12. Participating in other treatment clinical trials.",{"count":364,"type":20},712,[101,50],"Up to 50% of acute ischemic stroke patients with large vessel occlusion failed to achieve functional independence even after successful reperfusion therapy, a phenomenon that is referred to as \"futile recanalization\". The mechanism of futile recanalization is complex, and some studies have shown that it may be related to factors such as tissue no reflow, reocclusion, poor status of collateral circulation, hemorrhagic transformation, impaired cerebrovascular autonomic regulation, and low perfusion volume. Several studies suggested that maximizing the improvement of cerebral reperfusion is still the primary goal of acute large vessel occlusive stroke. Structural and functional alterations in the microvascular system may be a major obstacle to reperfusion. In animal models of cerebral ischemia, downstream microvascular thrombosis may occur in the early stage of cerebral ischemia and before vascular recanalization, which is the main factor leading to incomplete reperfusion and affecting the efficacy of endovascular thrombectomy.\n\nMechanical thrombectomy mainly addressed the occluded large arteries, and does not consider the distal arteries. However, the recanalization of occluded large arteries does not necessarily translate into successful reperfusion of the ischemic tissue supplied by the distal capillaries. Even with complete recanalization, impaired microcirculatory reperfusion may lead to poor clinical outcomes. Therefore, we speculate that at the end of endovascular thrombectomy, microthrombi remain present in the microcirculation of brain tissue in patients with complete or near-complete cerebral angiography, and that microthrombi is more likely to be dissolved than thrombus more proximal to the heart. Therefore, intra-arterial administration of pharmaceutical, such as tirofiban, may be the only possible option to ensure complete reperfusion of ischemic tissue. Tirofiban is a platelet glycoprotein IIb\u002FIIIa receptor antagonist, which has been widely used in acute coronary syndrome, and its role in acute ischemic stroke has attracted more and more attention from stroke experts. Previous studies have suggested that tirofiban can further increase the incidence of successful recanalization, while reducing the reocclusion rate.\n\nWhether early administration of intraarterial and intravenous tirofiban can further improve the clinical outcomes of patients with large vessel occlusive stroke after successful mechanical thrombectomy remains unclear.",[26],"2024-05-13",{"date":370,"type":31},"2024-05-16",{"date":372,"type":20},"2024-07-31",{"date":374,"type":20},"2026-10-31",{"name":88,"class":38},{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":383,"enrollmentInfo":384,"targetDuration":4,"studyType":316,"phases":4,"briefSummary":386,"conditions":387,"keywords":388,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":39},"100434811","establishing-mechanical-thrombectomy-at-a-limited-volume-stroke-center---effects-on-patient-morbidity-and-mortality-100434811","NCT04942041","Establishing Mechanical Thrombectomy at a Limited-volume Stroke Center - Effects on Patient Morbidity and Mortality","Establishing Mechanical Thrombectomy at a Limited-volume Stroke Center - Effects on Patient Morbidity and Mortality.","Inclusion Criteria:\n\n* Adult patients\n* Large vessel occlusion stroke\n\nExclusion Criteria:\n\n* Intracranial hemorrhage, tumor, aneurism or vascular malformation i the stroke area\n* More than 24 hours after stroke onset","100 Years",{"count":385,"type":20},300,"The regional health authorities of South-East Norway has commissioned Sørlandet Hospital (SSHF), Norway to establish mechanical thrombectomy in large-vessel occlusion stroke. SSHF is a limited volume stroke center, and introduction of thrombectomy may impose quality challenges. Therefore the implementation will be guided by a simulation based quality assurance program. In this study, we will monitor timelines, technical and clinical outcomes, including adverse events.",[26],[127,204,389,390],"Simulation","Quality program","2023-12-21",{"date":393,"type":31},"2023-12-29",{"date":395,"type":31},"2021-01-01",{"date":397,"type":20},"2026-12",{"name":399,"class":400},"Sorlandet Hospital HF","OTHER_GOV",{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":409,"targetDuration":411,"studyType":316,"phases":4,"briefSummary":412,"conditions":413,"keywords":416,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":66},"100489902","triage-of-patients-with-acute-ischemic-stroke-due-to-large-vessel-occlusions-2-100489902","NCT05659160","Triage of Patients With Acute Ischemic Stroke Due to Large Vessel Occlusions-2","Triage of Patients With Acute Ischemic Stroke Due to Large Vessel Occlusions-2 (TRACK-LVO-2): an Imaging-based Patient Registry Study","TRACK-LVO-2","Inclusion Criteria:\n\n1. Patient admitted from Jan. 1st 2018 to Jan. 1st 2028;\n2. Age ≥ 18;\n3. Ischemic stroke confirmed by head CT or MRI;\n4. Large vessel occlusion confirmed by head CTA or MRA: intracranial internal carotid artery (ICA), middle cerebral artery (MCA M1\u002FM2), anterior cerebral artery (ACA A1\u002FA2), basilar artery (BA), vertebral artery (VA), and posterior cerebral artery (PCA P1\u002FP2);\n5. Patients receiving either endovascular therapy or best medical treatment;\n\nExclusion Criteria:\n\n\\- None",{"count":410,"type":20},5000,"1 Year","The objective of this study is to create a comprehensive, real-world, multi-center observational registry of consecutive patients admitted to hospitals with acute ischemic stroke (AIS) caused by large vessel occlusions (LVO), who are treated with either endovascular therapy (EVT) or the best available medical management (BMM).",[26,414,415],"Endovascular Procedures","Large Vessel Occlusion",[417,418,415],"Acute Ischemic Stroke","Endovascular Therapy",{"date":420,"type":31},"2023-12-01",{"date":422,"type":31},"2021-11-01",{"date":424,"type":20},"2028-12-31",{"name":426,"class":38},"Tianjin Huanhu Hospital",{"id":428,"slug":429,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":21,"phases":437,"briefSummary":438,"conditions":439,"keywords":440,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":447,"leadSponsor":449,"locationsCount":4},"100524488","role-of-hypothermia-in-endovascular-stroke-thrombectomy-100524488","NCT06109376","Role of Hypothermia in Endovascular Stroke Thrombectomy","Efficacy and Safety of Endovascular Thrombectomy With Versus Without Hypothermia in Acute Large Vessel Occlusion Stroke: a Randomized Controlled Trial","COOLING","Inclusion Criteria:\n\n1. Aged ≥ 18 years or more;\n2. acute ischemic stroke within 24 hours from onset to randomization;\n3. NIHSS ≥6 points before randomization;\n4. Internal carotid artery, or the middle cerebral artery M1 or M2 occlusion confirmed by CTA\u002FMRA\u002FDSA;\n5. Baseline ASPECTS score ≥ 3 and ≤8, or cerebral infarction core volume \\\u003C 100ml;\n6. The patient decides to undergo endovascular therapy;\n7. The patient or patient's representative signs a written informed consent form.\n\nExclusion Criteria:\n\n1. CT or MR evidence of hemorrhage;\n2. Currently pregnant or lactating (women patients);\n3. Allergy to radiographic contrast agents, or nitinol devices;\n4. Arterial tortuosity and\u002For other arterial disease that would prevent the device from reaching the target vessel;\n5. Multiple vessel occlusion (e.g., bilateral anterior circulation, or occlusion of both anterior and posterior circulation);\n6. Preexisting neurological or psychiatric disease that would confound the neurological functional evaluations;\n7. Previous bleeding disorders, severe heart, liver or kidney disease, or sepsis;\n8. Brain tumors with mass effect (except meningiomas) that are radiographically pleasant;\n9. Intracranial aneurysm, arteriovenous malformation;\n10. Any terminal illness with life expectancy less than 6 months;\n11. Participating in other clinical trials.",{"count":436,"type":20},200,[23],"Reducing or suspending the increase of the infarcted core, i.e., \"freezing\" the ischemic penumbra, may help improve the efficacy of mechanical thrombectomy. Hypothermia effectively reduces the metabolic level of brain tissue, may prolong the time window for recanalization therapy, and its multi-target therapeutic effect make it one of the most promising neuro-protection approach.\n\nIn recent years, hypothermia has been increasingly used to treat acute ischemic stroke. However, its role in acute ischemic stroke is unclear.\n\nThe objective of this trial is to investigate whether hypothermia combined with endovascular thrombectomy could add additional benefit without increasing the risk of adverse events such as pneumonia, intracerebral hemorrhage, and mortality.",[26],[105,441,106,442],"hypothermia","randomized controlled trial","2023-10-25",{"date":445,"type":31},"2023-10-31",{"date":420,"type":20},{"date":448,"type":20},"2027-03-31",{"name":65,"class":38},{"id":451,"slug":452,"hasResults":11,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":11,"sex":16,"minAge":457,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":21,"phases":459,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":39},"100522541","phase-4-the-effect-of-early-administration-of-pcsk9-inhibitor-to-acute-ischemic-stroke-patients-associated-with-atherosclerosis-on-the-stroke-prognosis-and-lipid-profile-100522541","NCT06083961","The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile","The Effect of Early Administration of PCSK9 Inhibitor, Alirocumab to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile, a Single Center Study, Registry Based, Pragmatic, Prospective Trial","Inclusion Criteria:\n\n* Non-cardioembolic Stroke\n* Acute Ischemic stroke within 7 days of symptom onset (confirmed by CT or MRI)\n* Age 19 and above\n* Significant stenosis associated with atherosclerosis in major intracranial \u002F extracranial vessels.\n* National Institutes of Health Stroke Scale(NIHSS) score of 15 or less at admission\n* Patients with the capacity to consent for participation in the clinical trial.\n\nExclusion Criteria:\n\n* Presence of high-risk factors for cardioembolism\n* Risk of ischemic stroke due to thrombosis from other causes\n* Patients with hemorrhagic stroke, brain tumors, or brain abscesses\n* Patients unable to take statins or PCSK9 inhibitors\n* Pre-stroke mRS score of 3 or higher\n* Severe liver failure (liver enzyme \\> 3 times the upper normal limit) or renal failure (serum Creatinine \\> 2mg\u002FdL or estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73m2)\n* Anemia (hemoglobin \\\u003C 8mg\u002FdL) or thrombocytopenia (platelet count \\\u003C 100K)\n* Uncontrolled diabetes not managed by medication or insulin\n* Pregnant or breastfeeding patients\n* Patients already receiving PCSK-9 inhibitors\n* Patients deemed inappropriate for participation in the clinical trial by the investigator for other reasons.","19 Years",{"count":436,"type":20},[460],"PHASE4","The goal of this clinical trial is to test the effect of proprotein convertase subtilisin\u002Fkexin type 9 (PCSK9 inhibitors) in acute ischemic stroke patients associated with atherosclerosis by investigating\n\n1. the change in lipid profile compared to baseline results\n2. the effects on prognosis of stroke The participants will be given PCSK9 inhibitor right after confirmation of acute ischemic stroke, and the investigators will compare the results to the control group, whom are acute ischemic stroke patients treated with conventional lipid lowering therapy, statin and\u002For ezetimibe.",[26,463],"PCSK9 Inhibitor","2023-10-09",{"date":466,"type":31},"2023-10-16",{"date":468,"type":20},"2023-10-15",{"date":470,"type":20},"2026-11-15",{"name":472,"class":38},"Sun U. Kwon"]